Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Estrogen-progestin replacement therapy: regulatory action needed.

Malcolm C Pike1, Ronald K Ross

  • 1Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California 90033, USA. mcpike@usc.edu

Breast Cancer Research : BCR
|December 11, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differences in overall survival for invasive epithelial ovarian cancer by race and ethnicity: results from the Ovarian Cancer Association Consortium.

British journal of cancer·2026
Same author

Estrogen hormone therapy use in ovarian cancer patients under age 60 at diagnosis.

Gynecologic oncology·2026
Same author

Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma.

Nature communications·2026
Same author

Evaluating mammographic density polygenic risk score for contralateral breast cancer risk prediction.

Scientific reports·2026
Same author

Medroxyprogesterone Acetate Inhibits Tumorigenesis in Mouse Models of Oviductal High-Grade Serous Carcinoma.

Cancers·2025
Same author

Beyond <i>BRCA</i> deficiency: Clinical and molecular predictors of survival in patients with <i>BRCA</i>-deficient tubo-ovarian high-grade serous carcinoma.

medRxiv : the preprint server for health sciences·2025

The most common hormone replacement therapy (HRT) increases breast cancer risk. New intermediate risk markers are needed to assess other HRT regimens quickly and safely.

Area of Science:

  • Endocrinology
  • Oncology
  • Pharmacology

Background:

  • The established estrogen-progestin replacement therapy (HRT) regimen is linked to increased breast cancer risk.
  • Current research limitations prevent timely assessment of breast cancer risk for alternative HRT regimens.

Discussion:

  • There is a critical need to identify and utilize intermediate biomarkers of risk.
  • These markers can provide a probable, quantitative estimate of breast cancer risk associated with various HRT regimens.
  • This approach allows for faster risk assessment compared to long-term clinical studies.

Key Insights:

  • The limitations of breast cancer outcome studies necessitate the use of surrogate markers.
  • Intermediate risk markers offer a feasible method to evaluate the safety of diverse HRT formulations.

Related Experiment Videos

  • Adopting this strategy can accelerate the understanding of HRT's impact on cancer risk.

    • Outlook:

    • Regulatory bodies should mandate studies using intermediate risk markers for all current HRT regimens.
    • This will enable proactive risk management and informed clinical decision-making.
    • Future research should focus on validating these intermediate markers across different patient populations and HRT types.